Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2021 / N 2

Когнитивные нарушения у пациентов с артериальной гипертонией: фокус на пациентов среднего возраста
Т.М. Остроумова, О.Д. Остроумова

Список литературы

1. World Health Organization. Hypertension. Available from: https://www.who.int/health-topics/hypertension/ Accessed 2021 June 28.
2. Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration. Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment. The Lancet. Diabetes & Endocrinology 2014 Aug;2(8):634-47.
3. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2015 update: a report from the American Heart Association. Circulation 2015 Jan;131(4):e29-322.
4. NCD Risk Factor Collaboration (NCD-RisC). Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. The Lancet 2019 Aug;394(10199):639-51.
5. Баланова Ю.А., Шальнова С.А., Имаева А.Э., Капустина А.В., Муромцева Г.А., Евстифеева С.Е., Тарасов В.И., Редько А.Н., Викторова И.А., Прищепа Н.Н., Якушин С.С., Бойцов С.А., Драпкина О.М. от имени участников исследования ЭССЕ-РФ-2. Распространенность артериальной гипертонии, охват лечением и его эффективность в Российской Федерации (данные наблюдательного исследования ЭССЕ-РФ-2). Рациональная фармакотерапия в кардиологии 2019;15(4):450-66.
6. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; Authors/Task Force Members. 2018 ESC/ESH Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. European Heart Journal 2018 Oct;36(10):1953-2041.
7. GBD 2016 Dementia Collaborators. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet. Neurology 2019 Jan;18(1):88-106.
8. Ou YN, Tan CC, Shen XN, Xu W, Hou XH, Dong Q, Tan L, Yu JT. Blood pressure and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 209 prospective studies. Hypertension 2020 Jul;76(1):217-25.
9. Kishita N, Backhouse T, Mioshi E. Nonpharmacological interventions to improve depression, anxiety, and quality of life (QoL) in people with dementia: an overview of systematic reviews. Journal of Geriatric Psychiatry and Neurology 2020 Jan;33(1):28-41.
10. Farina N, Page TE, Daley S, Brown A, Bowling A, Basset T, Livingston G, Knapp M, Murray J, Banerjee S. Factors associated with the quality of life of family carers of people with dementia: a systematic review. Alzheimer’s & Dementia 2017 May;13(5):572-81.
11. Хороших Л.В. Гипертонические кризы: последние данные и обзор литературы. Креативная кардиология 2020;14(1):58-70.
12. Сырова И.Д., Ложкин И.С., Трубникова О.А., Артамонова А.И., Портнов Ю.М., Семенов С.Е., Малева О.В., Коваленко А.В., Гарганеева Н.П. Цереброваскулярные осложнения у пациентов с ишемической болезнью сердца, перенесших коронарное шунтирование (пятилетнее наблюдение). Креативная кардиология 2020;14(4):313-23.
13. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5). 5th ed. Washington, DC: American Psychiatric Publishing; 2013. 992 p.
14. Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chételat G, Dubois B, Dufouil C, Ellis KA, van der Flier WM, Glodzik L, van Harten AC, de Leon MJ, McHugh P, Mielke MM, Molinuevo JL, Mosconi L, Osorio RS, Perrotin A, Petersen RC, Rabin LA, Rami L, Reisberg B, Rentz DM, Sachdev PS, de la Sayette V, Saykin AJ, Scheltens P, Shulman MB, Slavin MJ, Sperling RA, Stewart R, Uspenskaya O, Vellas B, Visser PJ, Wagner M; Subjective Cognitive Decline Initiative (SCD-I) Working Group. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimer’s & Dementia 2014 Nov;10(6):844-52.
15. Коберская Н.Н., Остроумова Т.М. Доумеренное когнитивное снижение. Неврология, нейропсихиатрия, психосоматика 2020;12(2):92-7.
16. Debette S, Seshadri S, Beiser A, Au R, Himali JJ, Palumbo C, Wolf PA, DeCarli C. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology 2011 Aug;77(5):461-8.
17. Teles de Menezes S, Giatti L, Brant LCC, Griep RH, Schmidt MI, Duncan BB, Suemoto CK, Ribeiro ALP, Barreto SM. Hypertension, prehypertension, and hypertension control: association with decline in cognitive performance in the ELSA-Brasil cohort. Hypertension 2021 Feb;77(2):672-81.
18. Парфенов В.А., Остроумова Т.М., Остроумова О.Д., Борисова Е.В., Перепелов В.А., Перепелова В.М. Когнитивные функции, эмоциональный статус и показатели магнитно-резонансной томографии у нелеченых пациентов среднего возраста с неосложненной артериальной гипертензией. Журнал неврологии и психиатрии им. С.С. Корсакова 2018;118(8):23-32.
19. Кулеш АА, Дробаха ВЕ, Шестаков ВВ. Церебральная болезнь мелких сосудов: классификация, клинические проявления, диагностика и особенности лечения. Неврология, нейропсихиатрия, психосоматика 2019;11(Прил. 3):4-17.
20. Sierra C, de La Sierra A, Mercader J, Gómez-Angelats E, Urbano-Márquez A, Coca A. Silent cerebral white matter lesions in middle-aged essential hypertensive patients. Journal of Hypertension 2002 Mar;20(3):519-24.
21. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR. American Journal of Roentgenology 1987 Aug;149(2):351-6.
22. Kloppenborg RP, Nederkoorn PJ, Geerlings MI, van den Berg E. Presence and progression of white matter hyperintensities and cognition: a meta-analysis. Neurology 2014 Jun;82(23):2127-38.
23. Fanning JP, Wong AA, Fraser JF. The epidemiology of silent brain infarction: a systematic review of population-based cohorts. BMC Medicine 2014 Jul;12:119.
24. Lei C, Deng Q, Li H, Zhong L. Association between silent brain infarcts and cognitive function: a systematic review and meta-analysis. Journal of Stroke and Cerebrovascular Diseases 2019 Sep;28(9):2376-87.
25. Elmståhl S, Ellström K, Siennicki-Lantz A, Abul-Kasim K. Association between cerebral microbleeds and hypertension in the Swedish general population "Good Aging in Skåne" study. Journal of Clinical Hypertension 2019 Aug;21(8):1099-107.
26. Akoudad S, Wolters FJ, Viswanathan A, de Bruijn RF, van der Lugt A, Hofman A, Koudstaal PJ, Ikram MA, Vernooij MW. Association of cerebral microbleeds with cognitive decline and dementia. JAMA Neurology 2016 Aug;73(8):934-43.
27. Vicario A, Coca A, Gasecki D, Zaninelli A, Lovic D, Manios E, Hering D, Sierra C, Cunha P on behalf of the ESH WG on Hypertension and Brain. Effects of antihypertensive treatment on cognitive decline. European Society of Hypertension. Scientific Newsletter. Update on hypertension management. 2019;23.
28. Yagi S, Akaike M, Ise T, Ueda Y, Iwase T, Sata M. Renin-angiotensin-aldosterone system has a pivotal role in cognitive impairment. Hypertension Research 2013 Sep;36(9):753-8.
29. Sink KM, Leng X, Williamson J, Kritchevsky SB, Yaffe K, Kuller L, Yasar S, Atkinson H, Robbins M, Psaty B, Goff DC Jr. Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study. Archives of Internal Medicine 2009 Jul;169(13):1195-202.
30. Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B, Davies R, Ostergren J, Probstfield J; HOPE Investigators. Heart outcomes prevention evaluation. Use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002 Mar;324(7339):699-702.
31. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, Chalmers J; PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Archives of Internal Medicine 2003 May;163(9):1069-75.
32. Deb D, Bairy KL, Nayak V, Rao M. Comparative effect of lisinopril and fosinopril in mitigating learning and memory deficit in scopolamine-induced amnesic rats. Advances in Pharmacological Sciences 2015;2015:521718.
33. Остроумова О.Д., Голобородова И.В. Возможности применения комбинации ингибитора ангиотензинпревращающего фермента фозиноприла с недигидропиридиновым антагонистом кальция дилтиаземом как терапии первой линии в лечении артериальной гипертонии (клинический пример). Медицинский совет 2019;5:36-45.
34. Остроумова О.Д., Парфенов В.А., Остроумова Т.М., Яхно Н.Н., Чазова И.Е., Боголепова А.Н., Галявич А.С., Гераскина Л.А., Емелин А.Ю., Захаров В.В., Кисляк О.А., Кулеш А.А., Левин О.С., Подзолков В.И., Привалова Е.В., Ших Е.В. Консенсус экспертов. Влияние антигипертензивной терапии на когнитивные функции. Системные гипертензии 2021;18(1):5-12.
35. Levi Marpillat N, Macquin-Mavier I, Tropeano AI, Bachoud-Levi AC, Maison P. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. Journal of Hypertension 2013 Jun;31(6):1073-82.
36. Chiu WC, Ho WC, Lin MH, Lee HH, Yeh YC, Wang JD, Chen PC; Health Data Analysis in Taiwan (hDATa) Research Group. Angiotension receptor blockers reduce the risk of dementia. Journal of Hypertension 2014 Apr;32(4):938-47.
37. Hajjar I, Hart M, Chen YL, Mack W, Novak V, Chui HC, Lipsitz L. Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial. Journal of the American Geriatrics Society 2013 Feb;61(2):194-201.
38. Skoog I, Lithell H, Hansson L, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A; SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension 2005 Aug;18(8):1052-9.
39. Захаров В.В., Вахнина Н.В., Парфенов В.А. Когнитивные нарушения и их лечение при артериальной гипертензии. Медицинский Совет 2017;(S):6-12.
40. Старчина Ю.А., Захаров В.В.. Недементные когнитивные нарушения: роль нейрометаболической терапии. Эффективная фармакотерапия 2017:3:8-18.
41. Захаров В.В. Применение винпотропила при дисциркуляторной энцефалопатии с недементными когнитивными нарушениями. Журнал неврологии и психиатрии им. С.С. Корсакова 2010;110(11):13-6.
42. Громова О.А., Калачева А.Г., Торшин И.Ю., Гришина Т.Р., Томилова И.К. Тройственный синергизм этилметилгидроксипиридина сукцината, магния и витамина В6: молекулярные механизмы. Неврология, нейропсихиатрия, психосоматика 2017;9(1):42-9.
43. Alam AB, Lutsey PL, Gottesman RF, Tin A, Alonso A. Low serum magnesium is associated with incident dementia in the ARIC-NCS cohort. Nutrients 2020 Oct;12(10):3074.

References

1. World Health Organization. Hypertension. Available from: https://www.who.int/health-topics/hypertension/ Accessed 2021 June 28.
2. Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration. Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment. The Lancet. Diabetes & Endocrinology 2014 Aug;2(8):634-47.
3. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2015 update: a report from the American Heart Association. Circulation 2015 Jan;131(4):e29-322.
4. NCD Risk Factor Collaboration (NCD-RisC). Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. The Lancet 2019 Aug;394(10199):639-51.
5. Balanova YuA, Shalnova SA, Imayeva AE, Kapustina AV, Muromtseva GA, Yevstifeyeva SE, Tarasov VI, Redko AN, Viktorova IA, Prishchepa NN, Yakushin SS, Boytsov SA, Drapkina OM on behalf of ESSE-RF-2 researchers. Prevalence, awareness, treatment and control of hypertension in Russian Federation (Data of observational ESSE-RF-2 study). Rational Pharmacotherapy in Cardiology 2019;15(4):450-66 (In Russian).
6. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; Authors/Task Force Members. 2018 ESC/ESH Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. European Heart Journal 2018 Oct;36(10):1953-2041.
7. GBD 2016 Dementia Collaborators. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet. Neurology 2019 Jan;18(1):88-106.
8. Ou YN, Tan CC, Shen XN, Xu W, Hou XH, Dong Q, Tan L, Yu JT. Blood pressure and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 209 prospective studies. Hypertension 2020 Jul;76(1):217-25.
9. Kishita N, Backhouse T, Mioshi E. Nonpharmacological interventions to improve depression, anxiety, and quality of life (QoL) in people with dementia: an overview of systematic reviews. Journal of Geriatric Psychiatry and Neurology 2020 Jan;33(1):28-41.
10. Farina N, Page TE, Daley S, Brown A, Bowling A, Basset T, Livingston G, Knapp M, Murray J, Banerjee S. Factors associated with the quality of life of family carers of people with dementia: a systematic review. Alzheimer’s & Dementia 2017 May;13(5):572-81.
11. Khoroshikh LV. Hypertensive crises: recent evidence and literature review. Creative Cardiology 2020;14(1):58-70 (In Russian).
12. Syrova ID, Lozhkin IS, Trubnikova OA, Artamonova AI, Portnov YuM, Semenov SE, Maleva OV, Kovalenko AV, Garganeeva NP. Cerebrovascular complications in patients with coronary heart disease who underwent coronary bypass surgery (five-year follow-up). Creative Cardiology 2020;14(4):313-23 (In Russian).
13. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5). 5th ed. Washington, DC: American Psychiatric Publishing; 2013. 992 p.
14. Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chételat G, Dubois B, Dufouil C, Ellis KA, van der Flier WM, Glodzik L, van Harten AC, de Leon MJ, McHugh P, Mielke MM, Molinuevo JL, Mosconi L, Osorio RS, Perrotin A, Petersen RC, Rabin LA, Rami L, Reisberg B, Rentz DM, Sachdev PS, de la Sayette V, Saykin AJ, Scheltens P, Shulman MB, Slavin MJ, Sperling RA, Stewart R, Uspenskaya O, Vellas B, Visser PJ, Wagner M; Subjective Cognitive Decline Initiative (SCD-I) Working Group. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimer’s & Dementia 2014 Nov;10(6):844-52.
15. Koberskaya NN, Ostroumova TM. Near-moderate cognitive decline. Neurology, Neuropsychiatry, Psychosomatics 2020;12(2):92-7 (In Russian).
16. Debette S, Seshadri S, Beiser A, Au R, Himali JJ, Palumbo C, Wolf PA, DeCarli C. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology 2011 Aug;77(5):461-8.
17. Teles de Menezes S, Giatti L, Brant LCC, Griep RH, Schmidt MI, Duncan BB, Suemoto CK, Ribeiro ALP, Barreto SM. Hypertension, prehypertension, and hypertension control: association with decline in cognitive performance in the ELSA-Brasil cohort. Hypertension 2021 Feb;77(2):672-81.
18. Parfenov VA, Ostroumova TM, Ostroumova ОD, Borisova EV, Perepelov VA, Perepelova EM. Cognitive functions, emotional status, MRI measurements in treatment-naive middle-aged patients with uncomplicated essential arterial hypertension. SS Korsakov Journal of Neurology and Psychiatry 2018;118(8):23-32 (In Russian).
19. Kulesh AA, Drobakha VE, Shestakov VV. Cerebral small vessel disease: classification, clinical manifestations, diagnosis, and features of treatment. Neurology, Neuropsychiatry, Psychosomatics 2019;11(Suppl 3):4-17 (In Russian).
20. Sierra C, de La Sierra A, Mercader J, Gómez-Angelats E, Urbano-Márquez A, Coca A. Silent cerebral white matter lesions in middle-aged essential hypertensive patients. Journal of Hypertension 2002 Mar;20(3):519-24.
21. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR. American Journal of Roentgenology 1987 Aug;149(2):351-6.
22. Kloppenborg RP, Nederkoorn PJ, Geerlings MI, van den Berg E. Presence and progression of white matter hyperintensities and cognition: a meta-analysis. Neurology 2014 Jun;82(23):2127-38.
23. Fanning JP, Wong AA, Fraser JF. The epidemiology of silent brain infarction: a systematic review of population-based cohorts. BMC Medicine 2014 Jul;12:119.
24. Lei C, Deng Q, Li H, Zhong L. Association between silent brain infarcts and cognitive function: a systematic review and meta-analysis. Journal of Stroke and Cerebrovascular Diseases 2019 Sep;28(9):2376-87.
25. Elmståhl S, Ellström K, Siennicki-Lantz A, Abul-Kasim K. Association between cerebral microbleeds and hypertension in the Swedish general population "Good Aging in Skåne" study. Journal of Clinical Hypertension 2019 Aug;21(8):1099-107.
26. Akoudad S, Wolters FJ, Viswanathan A, de Bruijn RF, van der Lugt A, Hofman A, Koudstaal PJ, Ikram MA, Vernooij MW. Association of cerebral microbleeds with cognitive decline and dementia. JAMA Neurology 2016 Aug;73(8):934-43.
27. Vicario A, Coca A, Gasecki D, Zaninelli A, Lovic D, Manios E, Hering D, Sierra C, Cunha P on behalf of the ESH WG on Hypertension and Brain. Effects of antihypertensive treatment on cognitive decline. European Society of Hypertension. Scientific Newsletter. Update on hypertension management. 2019;23.
28. Yagi S, Akaike M, Ise T, Ueda Y, Iwase T, Sata M. Renin-angiotensin-aldosterone system has a pivotal role in cognitive impairment. Hypertension Research 2013 Sep;36(9):753-8.
29. Sink KM, Leng X, Williamson J, Kritchevsky SB, Yaffe K, Kuller L, Yasar S, Atkinson H, Robbins M, Psaty B, Goff DC Jr. Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study. Archives of Internal Medicine 2009 Jul;169(13):1195-202.
30. Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B, Davies R, Ostergren J, Probstfield J; HOPE Investigators. Heart outcomes prevention evaluation. Use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002 Mar;324(7339):699-702.
31. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, Chalmers J; PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Archives of Internal Medicine 2003 May;163(9):1069-75.
32. Deb D, Bairy KL, Nayak V, Rao M. Comparative effect of lisinopril and fosinopril in mitigating learning and memory deficit in scopolamine-induced amnesic rats. Advances in Pharmacological Sciences 2015;2015:521718.
33. Ostroumova OD, Goloborodova IV. Combination of angiotensin converting enzyme inhibitor fosinopril with non-dihydropyridine calcium antagonist diltiazem as first-line therapy in treatment of arterial hypertension: clinical case. Medical Council 2019;5:36-45 (In Russian).
34. Ostroumova OD, Parfenov VA, Ostroumova TM, Yakhno NN, Chazova IE, Bogolepova AN, Galyavich AS, Geraskina LA, Yemelin AI, Zakharov VV, Kislyak OA, Kulesh AA, Levin OS, Podzolkov VI, Privalova EV, Shikh EV. Expert consensus. Effect of antihypertensive therapy on cognitive functions. Systemic Hypertension 2021;18(1):5-12 (In Russian).
35. Levi Marpillat N, Macquin-Mavier I, Tropeano AI, Bachoud-Levi AC, Maison P. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. Journal of Hypertension 2013 Jun;31(6):1073-82.
36. Chiu WC, Ho WC, Lin MH, Lee HH, Yeh YC, Wang JD, Chen PC; Health Data Analysis in Taiwan (hDATa) Research Group. Angiotension receptor blockers reduce the risk of dementia. Journal of Hypertension 2014 Apr;32(4):938-47.
37. Hajjar I, Hart M, Chen YL, Mack W, Novak V, Chui HC, Lipsitz L. Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial. Journal of the American Geriatrics Society 2013 Feb;61(2):194-201.
38. Skoog I, Lithell H, Hansson L, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A; SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension 2005 Aug;18(8):1052-9.
39. Zakharov VV, Vakhnina NV, Parfenov VA. Cognitive disorders and their treatment in hypertension. Medical Council 2017;(Suppl):6-12 (In Russian).
40. Starchina YuA, Zakharov VV. Cognitive impairment of non-dementia origin: role of neurometabolic therapy. Effective Pharmacotherapy 2017;3:8-18 (In Russian).
41. Zakharov VV. Vinpotropil in treatment of dyscirculatory encephalopathy with cognitive impairment without dementia. SS Korsakov Journal of Neurology and Psychiatry 2010;110(11):13-6 (In Russian).
42. Gromova OA, Kalacheva AG, Torshin IYu, Grishina TR, Tomilova IK. Triple synergy of ethylmethylhydroxypyridine succinate, magnesium, and vitamin B6: molecular mechanisms. Neurology, Neuropsychiatry, Psychosomatics 2017;9(1):42-9 (In Russian).
43. Alam AB, Lutsey PL, Gottesman RF, Tin A, Alonso A. Low serum magnesium is associated with incident dementia in the ARIC-NCS cohort. Nutrients 2020 Oct;12(10):3074.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]